Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance

  • STATUS
    Recruiting
  • End date
    May 31, 2025
  • participants needed
    70
  • sponsor
    Abbott Medical Devices
Updated on 19 February 2024

Summary

The purpose of this post-marketing clinical use database surveillance is to observe the frequency, type, and degree of adverse device effects and adverse events in order to assure the safety of the medical device, and to collect safety and efficacy information for evaluating the results of its clinical use.

Description

The Surveillance will be conducted per the standards required by the Ministry of Health, Labour and Welfare (MHLW) and in the standards for post-marketing surveillances and studies [except for those defined in the Ministerial Ordinance on Good Clinical Practice for Medical Devices (MHLW Ordinance No. 36, 2005)] based on Paragraph 4, Article 23-2-9 (including application mutatis mutandis per Article 23-2-19 of Revised PAL) of the Law on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices, etc. (Law No. 145, 1960, hereinafter referred to as "Revised PAL") by the Marketing Authorization Holder or accredited foreign manufacturer of a medical device defined in Paragraph 1, Article 23-2-5 of Revised PAL.

Details
Condition Congenital Heart Defect, Congenital Heart Disease, Patent ductus arteriosus, Congenital Heart Disease
Age 100 years and younger
Treatment Amplatzer Piccolo Occluder
Clinical Study IdentifierNCT04371081
SponsorAbbott Medical Devices
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

The device is used to percutaneously close the PDA of a patient who meets all
of the
following
PDA 4 mm in diameter
PDA 3 mm in length
Weight 700 g

Exclusion Criteria

Age <3 days
Coarctation of the aorta
Left pulmonary artery stenosis
Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary hypertension
Thrombus in the implant site, or sign of venous thrombus in a vessel in which the occluder is inserted and delivered
Endocarditis, or infection that can cause bacteremia
Allergic or potentially allergic to nickel
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.